ArticleOncoimmunology
Tumor lysis with LTX-401 creates anticancer immunity.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo.Molecular pharmaceutics · 2026Article
- Immunobiological mechanisms of action of oncolytic peptides.Journal for immunotherapy of cancer · 2026Review
- The Invertebrate-Derived Antimicrobial Peptide Cm-p5 Induces Cell Death and ROS Production in Melanoma Cells.Marine drugs · 2025Article
- Enhancing the therapeutic impact of sublethal radiofrequency hyperthermia in malignant solid tumor treatment.Heliyon · 2024Review
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Cell death discovery · 2024Article
- Molecular determinants of immunogenic cell death elicited by radiation therapy.Immunological reviews · 2024Review
- Immunogenic oncolysis by tigilanol tiglate.Oncoimmunology · 2024Article
- From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy.Bioactive materials · 2024Review
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Research square · 2023Article
- Anti-Cancer Peptides: Status and Future Prospects.Molecules (Basel, Switzerland) · 2023Review
- The marine natural product mimic MPM-1 is cytolytic and induces DAMP release from human cancer cell lines.Scientific reports · 2022Article
- PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.Oncoimmunology · 2022Article
- Lessons from a Single Amino Acid Substitution: Anticancer and Antibacterial Properties of Two Phospholipase ACurrent issues in molecular biology · 2021Article
- Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer.Scientific reports · 2021Article
- Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.Frontiers in oncology · 2021Review
- Interventional Optical Imaging-Monitored Synergistic Effect of Radio-Frequency Hyperthermia and Oncolytic Immunotherapy.Frontiers in oncology · 2021Article
- Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.Frontiers in immunology · 2021Review
- Peptides that immunoactivate the tumor microenvironment.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Calreticulin and cancer.Cell research · 2021Review
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.Nature reviews. Clinical oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and that sequential local inoculation of LTX-401 was able to cure immunocompetent host from subcutaneous MCA205 and TC-1 cancers. Cured animals exhibited long-term immune memory effects that rendered them resistant to rechallenge with syngeneic tumors. Nevertheless, the local treatment with LTX-401 alone had only limited abscopal effects on secondary contralateral lesions. Anticancer effects resulting from single as well as sequential injections of LTX-401 were boosted in combination with PD-1 and CTLA-4 immune checkpoint blockade (ICB), and sequential LTX-401 treatment combined with double ICB exhibited strong abscopal antineoplastic effects on contralateral tumors underlining the potency of this combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.